Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.

McLean LP, Shea-Donohue T, Cross RK.

Immunotherapy. 2012 Sep;4(9):883-98. doi: 10.2217/imt.12.85. Review.

2.

Vedolizumab: A New Opponent in the Battle Against Crohn's Disease and Ulcerative Colitis.

Poulakos M, Machin JD, Pauly J, Grace Y.

J Pharm Pract. 2016 Oct;29(5):503-15. doi: 10.1177/0897190015579610. Epub 2015 May 6. Review.

PMID:
25952593
3.

Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.

Hagan M, Cross RK.

Expert Opin Drug Saf. 2015;14(9):1473-9. doi: 10.1517/14740338.2015.1063612. Epub 2015 Jul 9. Review.

PMID:
26138111
4.

Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.

Garnock-Jones KP.

BioDrugs. 2015 Feb;29(1):57-67. doi: 10.1007/s40259-014-0113-2. Review. Erratum in: BioDrugs. 2015 Feb;29(1):73.

PMID:
25502899
5.

[Current position on Vedolizumab for ulcerative colitis and Crohn's disease].

Schreiber S, Dignass AU, Hartmann H, Kruis W, Rogler G, Siegmund B, Stallmach A, Witte C, Bokemeyer B.

Z Gastroenterol. 2015 Jun;53(6):591-602. doi: 10.1055/s-0034-1399400. Epub 2015 May 27. Review. German.

6.

Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.

McLean LP, Cross RK.

Expert Opin Drug Metab Toxicol. 2016 Jul;12(7):833-42. doi: 10.1080/17425255.2016.1181171. Epub 2016 May 12. Review. Erratum in: Expert Opin Drug Metab Toxicol. 2016 Jul;12 (7):v.

7.

Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.

Lam MC, Bressler B.

Immunotherapy. 2014;6(9):963-71. doi: 10.2217/imt.14.66.

PMID:
25341118
8.

An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.

Wyant T, Fedyk E, Abhyankar B.

J Crohns Colitis. 2016 Dec;10(12):1437-1444. Epub 2016 Jun 1. Review.

PMID:
27252400
9.

Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.

Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C.

Aliment Pharmacol Ther. 2016 Dec;44(11-12):1199-1212. doi: 10.1111/apt.13813. Epub 2016 Oct 7.

PMID:
27714831
10.

Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.

Smith MA, Mohammad RA.

Ann Pharmacother. 2014 Dec;48(12):1629-35. doi: 10.1177/1060028014549799. Epub 2014 Sep 3. Review.

PMID:
25186623
11.

The role of integrin antagonists in the treatment of inflammatory bowel disease.

Beniwal-Patel P, Saha S.

Expert Opin Biol Ther. 2014 Dec;14(12):1815-23. doi: 10.1517/14712598.2014.967209. Epub 2014 Oct 7. Review.

PMID:
25288228
12.

Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis.

Hahn L, Beggs A, Wahaib K, Kodali L, Kirkwood V.

Am J Health Syst Pharm. 2015 Aug 1;72(15):1271-8. doi: 10.2146/ajhp140449. Review.

PMID:
26195652
13.

The safety of vedolizumab for ulcerative colitis and Crohn's disease.

Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG.

Gut. 2017 May;66(5):839-851. doi: 10.1136/gutjnl-2015-311079. Epub 2016 Feb 18.

14.

Vedolizumab for the treatment of ulcerative colitis.

Rietdijk ST, D'Haens GR.

Expert Rev Clin Pharmacol. 2014 Jul;7(4):423-30. doi: 10.1586/17512433.2014.911084. Epub 2014 May 6. Review.

PMID:
24802046
15.

Vedolizumab: first global approval.

Poole RM.

Drugs. 2014 Jul;74(11):1293-303. doi: 10.1007/s40265-014-0253-1. Review.

PMID:
24985716
16.

Vedolizumab for the treatment of ulcerative colitis.

Shahidi N, Bressler B, Panaccione R.

Expert Opin Biol Ther. 2016;16(1):129-35. doi: 10.1517/14712598.2016.1121231. Epub 2015 Dec 9. Review.

PMID:
26567768
17.

Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.

Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, Sandborn WJ, Feagan BG, Reinisch W, Fox I.

Aliment Pharmacol Ther. 2015 Jul;42(2):188-202. doi: 10.1111/apt.13243. Epub 2015 May 20. Erratum in: Aliment Pharmacol Ther. 2015 Nov;42(9):1135.

18.

Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.

Yajnik V, Khan N, Dubinsky M, Axler J, James A, Abhyankar B, Lasch K.

Adv Ther. 2017 Feb;34(2):542-559. doi: 10.1007/s12325-016-0467-6. Epub 2017 Jan 9.

19.

Natalizumab for induction of remission in Crohn's disease.

Macdonald JK, McDonald JW.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD006097. Review. Update in: Cochrane Database Syst Rev. 2007;(1):CD006097.

PMID:
16856112
20.

Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.

McLean LP, Cross RK.

Expert Opin Investig Drugs. 2016;25(3):263-73. doi: 10.1517/13543784.2016.1148137. Review.

Supplemental Content

Support Center